India's Pharma Power: Sai Life Sciences to Add 700+ Jobs in FY27

HYDERABAD, India – February 20, 2026 – Sai Life Sciences Limited, a leading Indian contract research, development, and manufacturing organization (CRDMO), has announced a major recruitment drive, signaling deep confidence in its growth trajectory and India's expanding role in the global pharmaceutical landscape. The company plans to hire over 700 scientific, technical, and management professionals during the 2026–27 fiscal year, a move designed to scale its capabilities amid surging international demand.

This significant expansion is more than just a corporate growth story; it serves as a potent indicator of a broader strategic realignment within the global pharmaceutical industry. As innovator companies seek to build more resilient and diversified supply chains, Indian CRDMOs are stepping up to meet the demand for integrated, high-quality scientific partnerships. The hiring spree, which will bolster a workforce already exceeding 3,400 professionals, highlights a pivotal moment for India's life sciences sector as it transitions from a manufacturing hub to a center for complex, end-to-end drug development.

A Global Realignment Fuels Indian Growth

The decision by Sai Life Sciences is set against the backdrop of a booming global CRDMO market, valued at nearly $200 billion in 2023 and projected to exceed $325 billion by 2029. A key driver of this expansion is the strategic imperative for Western pharmaceutical giants to de-risk their supply chains, a trend widely known as the "China+1" strategy. This global rebalancing is creating a multi-billion-dollar opportunity for countries that can offer a stable, cost-effective, and high-quality alternative.

India is emerging as the primary beneficiary of this shift. The nation's CRDMO sector, though currently holding a modest 2-3% of the global market, is growing at an impressive 15% compound annual growth rate—significantly outpacing the industry average. This growth is fueled by a compelling value proposition that combines 30-40% lower R&D costs with a large pool of skilled STEM graduates and a strong record of regulatory compliance with bodies like the US FDA and EU GMP.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, identified this unique convergence of factors. “We are at an inflection point for the Indian CRDMO industry,” he stated. “Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale.”

Investing in High-Science Capabilities

Sai Life Sciences' expansion is not merely about increasing headcount; it is a strategic investment in deepening its scientific prowess. The recruitment will target a wide array of specialized roles, including medicinal chemistry, biology, DMPK, process engineering, and formulation development. A particular focus is being placed on attracting what the company calls 'high-calibre scientists' from leading institutions globally, reflecting the increasingly complex drug development programs being outsourced to India.

The company’s robust financial health underpins the feasibility of this ambitious plan. For the fiscal year ending in 2025, Sai Life Sciences reported a remarkable 105% surge in net profit on the back of 16% revenue growth. This strong performance has enabled significant capital allocation, with over ₹400 crore invested in FY25 to enhance manufacturing and discovery capabilities. The new roles will directly support growing client needs in cutting-edge areas such as complex small-molecule synthesis, data-enabled drug discovery, and commercial manufacturing scale-up.

This phase of growth is also being positioned as a compelling opportunity for scientific talent. “For scientists, this is a genuinely exciting moment,” Krishna Kanumuri added. “They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here.”

Hyderabad's Ascent as a Life Sciences Supercluster

The vast majority of the 700+ new positions will be based at the company's sprawling integrated R&D campus in Hyderabad, further cementing the city's status as India's premier life sciences hub. Home to Genome Valley, the country's first organized life sciences cluster, Hyderabad hosts over 2,000 pharmaceutical and biotech companies and contributes nearly one-third of India's total pharmaceutical production.

Sai Life Sciences is not alone in its expansion efforts. The city is witnessing a wave of investment from both domestic and international players. Competitors like Syngene International are committing hundreds of crores to new facilities, while pharmaceutical giants such as Novartis and Sanofi have massively scaled their Global Capability Centers (GCCs) in the city, turning them into strategic hubs for R&D and global operations. This industry-wide expansion is part of a larger government-backed vision for the state of Telangana, which aims to attract $25 billion in investments and create half a million high-value jobs in the sector by 2030.

This rapid industrial growth is transforming the local economy, fueling a real estate boom and driving significant infrastructure development. Mega-projects like the 19,000-acre Hyderabad Pharma City are expected to create hundreds of thousands of direct and indirect jobs, solidifying the region's critical role in the global pharmaceutical ecosystem.

The Race for Talent in a Booming Sector

While the influx of investment is a clear positive, it also intensifies the competition for a finite pool of specialized talent. Projections suggest that India's CRDMO sector may need to increase its workforce by as much as seven-fold by 2035 to realize its full growth potential. This puts immense pressure on companies to attract, train, and retain top-tier scientists and technicians.

In this competitive landscape, Sai Life Sciences' recruitment drive is a strategic move to secure the human capital necessary for future success. The company is deploying a multi-pronged talent strategy that includes a global alumni engagement platform and enhanced internal mobility and leadership development programs. The broader ecosystem is also responding to the challenge, with the Telangana government planning a dedicated Life Sciences School and fostering stronger partnerships between industry and academia to build a sustainable talent pipeline.

The hunt for 700 professionals is therefore a microcosm of a larger national endeavor: to build the scientific workforce required to power India's ambition of becoming a global leader in drug discovery and development. This expansion is a clear statement that Indian companies are ready to compete not just on cost, but on the depth of their scientific expertise and the quality of their innovation.